- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Register
- Orphan products
- Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methy
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]
EU orphan designation number: | EU/3/09/715
![]() |
Active ingredient: | Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] |
Indication: | Treatment of acute lymphoblastic leukaemia |
Sponsor: | Incyte Biosciences UK Ltd
Riverbridge House, Guildford Road, Leatherhead, Surrey KT22 9AD, United Kingdom |
EU Centralised marketing authorisation: | A centralised EU marketing authorisation has been obtained under the name Iclusig on 01/07/2013 with the number EU/1/13/839 |
Public summary of scientific opinion
EPAR
European Commission procedures |